Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2020 Results Earnings Conference Call November 12, 2020 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Strategy Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James Operator Welcome to the conference call hosted by Daré Bioscience to review the Company's Financial Results for the Quarter Ended September 30, 2020, and to provide a general business update. This cal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) Commission File No. ...

Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2020 Results Earnings Conference Call August 12, 2020 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Strategy Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants Nathan Weinstein - Aegis Capital Joanne Lee - the Maxim Group Operator Welcome to the conference call hosted by Daré Bioscience to review the Company's Financial Results for the Quarter Ended June 30, 2020, and to provide a general ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) Commission File No. 001-3 ...

Financial Data and Key Metrics Changes - For the quarter ended March 31, 2020, the company's general and administrative expenses were approximately $1.9 million, licensed expenses were $12,500, and research and development expenses were approximately $2.4 million [49][50] - The comprehensive loss for the quarter was approximately $4.3 million, with net cash provided by financing activities amounting to approximately $6.9 million [51][52] - The company ended the first quarter with approximately $5 million in cash and cash equivalents, indicating a need for additional capital to advance its programs [52][56] Business Line Data and Key Metrics Changes - The company is focused on three main programs: DARE-BV1 for bacterial vaginosis, Sildenafil Cream for female sexual arousal disorder, and Ovaprene as a hormone-free contraceptive [9][31][32] - DARE-BV1 has shown a clinical cure rate of 86% in a proof-of-concept study, significantly higher than currently marketed products [17][18] - The Sildenafil Cream program is expected to report topline results from a Phase 2b study in 2021, with the potential to be the first FDA-approved treatment for female sexual arousal disorder [9][29] Market Data and Key Metrics Changes - The market for female sexual arousal disorder is estimated to be as large or larger than the erectile dysfunction market, with 33% of women aged 21 to 60 experiencing symptoms [28] - The prevalence of bacterial vaginosis is estimated to impact over 20 million women in the U.S. alone, highlighting a significant market opportunity for DARE-BV1 [9][16] Company Strategy and Development Direction - The company aims to accelerate the availability of new prescription products in women's health by advancing product candidates that have the potential to be first-in-category [7] - The partnership with Bayer for Ovaprene is seen as a validation of the product's market potential and a strategic move to enhance the company's profile in women's health [35][40] - The collaboration with Health Decisions is expected to provide efficiencies in clinical program timelines and cost structures, enhancing the company's ability to advance its portfolio [42][60] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the potential disruptions caused by the COVID-19 pandemic but remains optimistic about meeting clinical and regulatory milestones [11][12] - The company is closely monitoring the evolving circumstances related to COVID-19 and its impact on business operations and financial conditions [56][57] - Management expressed confidence in maintaining timelines for clinical trials, particularly for the bacterial vaginosis program, due to the nature of the condition requiring in-person consultations [68][70] Other Important Information - The company has raised additional cash through various means, including a recent purchase agreement with Lincoln Park Capital Fund for the potential sale of up to $15 million in shares [54][55] - The company plans to file an investigational device exemption application for Ovaprene this year, with the expectation of initiating a pivotal clinical study in 2021 [36][37] Q&A Session Summary Question: Can you provide some color on how much faster the partnership with Health Decisions allows you to move your clinical program? - Management highlighted that the partnership provides efficiencies in time and cost, allowing for real-time engagement and quicker initiation of activities [60][63] Question: How many sites does the partnership involve and what types of trials are their expertise? - The partnership involves a large number of sites focused on women's health, particularly in contraception and vaginal health, leveraging Health Decisions' extensive experience [65] Question: How has the company maintained timelines amidst COVID-19 disruptions? - Management noted that the nature of bacterial vaginosis requires in-person consultations, allowing the study to proceed as planned, supported by the partnership with Health Decisions [68][70] Question: Do you expect R&D expenses to remain about $2.5 million a quarter for the rest of this year? - Management indicated that R&D expenses will vary and are not expected to be linear, depending on the progression of various programs [79][80] Question: How many patients will be enrolled in the Ovaprene trial? - The expected enrollment for the Ovaprene trial is around 250 subjects, as it is regulated under the device division of the FDA [81] Question: What will be the placebo control for the Ovaprene trial? - There will be no placebo arm in the contraceptive studies; all participants will receive the study drug, and pregnancy rates will be monitored [84]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) Commission File No. 001- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________ FORM 10-K ___________________________________________________ x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO_____ Commission File No. 001-36395 DARÉ BIOSCIENCE, INC. (Exa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) Commission File No. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) Commission File No. 001-3 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) Commission File No. 001- ...